2131-62-6

Usage

Uses

Used in Chemical Synthesis:
4-CARBOXYPHENYL ISOTHIOCYANATE is used as a chemical intermediate for the synthesis of various organic compounds. Its reactivity and structural features make it a valuable building block in the development of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
4-CARBOXYPHENYL ISOTHIOCYANATE is used as a key component in the development of pharmaceutical drugs. Its unique chemical structure allows it to interact with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Agrochemical Industry:
4-CARBOXYPHENYL ISOTHIOCYANATE is used as a starting material for the synthesis of agrochemicals, such as pesticides and herbicides. Its properties enable the development of effective compounds that can protect crops from pests and diseases.
Used in Dye and Pigment Industry:
4-CARBOXYPHENYL ISOTHIOCYANATE is used as a precursor for the production of dyes and pigments. Its chemical structure can be modified to create a wide range of colors, making it a versatile compound for the dye and pigment industry.
Used in Analytical Chemistry:
4-CARBOXYPHENYL ISOTHIOCYANATE is used as a reagent in analytical chemistry for the detection and quantification of various compounds. Its unique chemical properties make it a valuable tool for researchers in the field.

InChI:InChI=1/C8H5NO2S/c10-8(11)6-1-3-7(4-2-6)9-5-12/h1-4H,(H,10,11)/p-1

Upstream product

• 463-71-8 thiophosgene 
• 150-13-0 4-amino-benzoic acid 
• 75-15-0 carbon disulfide 

Downstream Products

• 131567-66-3 4-[N'-(4-acetyl-phenyl)-thioureido]-benzoic acid 
• 33942-52-8 4,4'-thiocarbonyldiamino-bis-benzoic acid 
• 6637-30-5 4-[N'-(4-sulfamoyl-phenyl)-thioureido]-benzoic acid 
• 136603-33-3 1-Benzyl-3-[3-(4-carboxy-phenyl)-thioureido]-1H-pyrazole-4-carboxylic acid ethyl ester 
• 138480-81-6 4-(4-Oxo-6-thioxo-2,4,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-5-yl)-benzoic acid 
• 136603-47-9 4-(4-Oxo-2,4-dihydro-pyrazolo[3,4-d][1,3]thiazin-6-ylamino)-benzoic acid 
• 136603-42-4 4-(2-Benzyl-4-oxo-2,4-dihydro-pyrazolo[3,4-d][1,3]thiazin-6-ylamino)-benzoic acid 
• 138480-79-2 4-(2-Benzyl-4-oxo-6-thioxo-2,4,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-5-yl)-benzoic acid 
• 136993-46-9 4-(2-Benzyl-6-methylsulfanyl-4-oxo-2,4-dihydro-pyrazolo[3,4-d]pyrimidin-5-yl)-benzoic acid 
• 611213-97-9 4-({1-methyl-5-[2-(N-methylcarbamoyl)(4-pyridyloxy)]benzimidazol-2-yl}amino)benzoic acid 
• 356773-81-4 4-[(3-methyl-4-oxo-1,3-thiazolan-2-yliden)amino]benzoic acid 
• 7366-56-5 4-thioureidobenzoic acid 

Relevant academic research and scientific papers

Synthesis and photophysical characterization of proton transfer-based thiourea derivatives: Potential application as colorimetric naked-eye chemosensor for fluoride detection in solution

Two new thiourea derivatives were synthesized through the reaction of photoactive aminohydroxybenzazoles and p-isothiocyanate benzoic acid via nucleophilic addition reaction. The compounds were characterized using high resolution mass spectrometry with el

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action

Protein CK2 has gained much interest as an anticancer drug target in the past decade. We had previously described the identification of a new allosteric site on the catalytic α-subunit, along with first small molecule ligands based on the 4-(4-phenylthiazol-2-ylamino)benzoic acid scaffold. In the present work, structure optimizations guided by a binding model led to the identification of the lead compound 2-hydroxy-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (27), showing a submicromolar potency against purified CK2α (IC50 = 0.6 μM). Furthermore, 27 induced apoptosis and cell death in 786-O renal cell carcinoma cells (EC50 = 5 μM) and inhibited STAT3 activation even more potently than the ATP-competitive drug candidate CX-4945 (EC50 of 1.6 μM vs 5.3 μM). Notably, the potencies of our allosteric ligands to inhibit CK2 varied depending on the individual substrate. Altogether, the novel allosteric pocket was proved a druggable site, offering an excellent perspective to develop efficient and selective allosteric CK2 inhibitors.

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site

CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various signaling pathways and is known to be constitutively active. In the present study, we identified aryl 2-aminothiazoles as a novel class of CK2 inhibitors, which displayed a non-ATP-competitive mode of action and stabilized an inactive conformation of CK2 in solution. Enzyme kinetics studies, STD NMR, circular dichroism spectroscopy, and native mass spectrometry experiments demonstrated that the compounds bind in an allosteric pocket outside the ATP-binding site. Our data, combined with molecular docking studies, strongly suggested that this new binding site was located at the interface between the αC helix and the flexible glycine-rich loop. A first hit optimization led to compound 7, exhibiting an IC50 of 3.4 μM against purified CK2α in combination with a favorable selectivity profile. Thus, we identified a novel class of CK2 inhibitors targeting an allosteric pocket, offering great potential for further optimization into anticancer drugs.

Synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase

A series of 4-thiazolidinone derivatives were synthesized and evaluated as novel human dihydroorotate dehydrogenase (hDHODH) inhibitors. Compounds 26 and 31 displayed IC50 values of 1.75 and 1.12 μM, respectively. The structure-activity relationship was summarized. Further binding mode analysis revealed that compound 31 could form a hydrogen bond with Tyr38 and a water-mediated hydrogen bond with Ala55, which may be necessary for maintaining the bioactivities of the compounds in this series. Further structural optimization of the para- or meta-position of the phenyl group at R will lead to the identification of more potent hDHODH inhibitors.

Facile and versatile synthesis of alkyl and aryl isothiocyanates by using triphosgene and cosolvent

A mild and efficient method for the conversion of alkyl and aryl amines to isothiocyanates via dithiocarbamates has been developed using (CH 3)2CO-CS2 as co-solvent and triphosgene as dehydrosulfurization reagent. High yields, mild reaction conditions and excellent functional group compatibility make it become a versatile synthetic method for the preparation of isothiocyanates compared with reported methods. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity

Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.

COMPOSITIONS FOR CONTROLLING VASCULARIZATION IN OPHTHALMOLOGICAL AND DERMATOLOGICAL DISEASES

A treatment method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having formula (I) or a pharmaceutically acceptable salt, hydrate, enantiomer, diastereomer, rac

Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases

A method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having or a pharmaceutically acceptable salt, hydrate, enantiomer, diastereomer, racemate or mixtures of s

METHOD FOR PRODUCING ISOTHIOCYANATE COMPOUND

The object of the present invention is to provide a novel method for producing an isothiocyanate compound having a carboxyl group(s) by a reaction of the corresponding amino compound having a carboxyl group(s), thiocarbonyldiimidazole and a base, in one s

METHOD FOR PRODUCING ISOTHIOCYANATE COMPOUND HAVING CARBOXYL GROUP

To provide a novel method for producing an isothiocyanate compound having a carboxyl group(s) from the corresponding amino compound having a carboxyl group(s). A method for producing an isothiocyanate compound which has a carboxyl group(s) and is represented by the formula (2). And the method comprises reacting an amino compound which has a carboxyl group(s) and is represented by the formula (1) (wherein A is e.g. a C6-14 aromatic hydrocarbon group or a C1-12 saturated hydrocarbon group, and B is e.g. a single bond, a C6-14 aromatic hydrocarbon group or a C1-12 saturated hydrocarbon group), in a solvent, with carbon disulfide (CS2) and then with a halogen as a simple substance.